Efficacy and safety of desmopressin orally disintegrating tablets 25 and 50 μg in male patients with nocturia: A Japanese real‐world multicenter clinical study. Issue 6 (5th August 2022)

• Record Type: Journal Article
• Authors: Kyoda, Yuki; Kimura, Makoto; Shimizu, Takashi; Miyao, Noriomi; Ogasawara, Takuto; Shimizu, Toshiaki; Iwasawa, Akihiko; Yorozuya, Wakako; Hashimoto, Jiro; Ichihara, Koji; Takei, Fumiyasu; Uchida, Kosuke; Kouzen, Nodoka; Suzuki, Noriyoshi; Tachikawa, Kimihito; Shibuya, Akihiko; Muranaka, Ippei; Okada, Manabu; Igarashi, Manabu; Shibamori, Kosuke; Nofuji, Seisuke; Fujino, Keiko; Toyota, Tomohiro; Ito, Yu; Shinkai, Nobuo; Hashimoto, Kohei; Kobayashi, Ko; Tanaka, Toshiaki; Masumori, Naoya
• Is Part Of: LUTS. Volume 14:Issue 6(2022)
• Page Start: 410
• Page End: 415
• Publication Date: 2022-08-05
• Subjects: desmopressin -- Japan -- nocturia -- nocturnal polyuria; Urology -- Periodicals; Urologic Diseases -- Periodicals; Urinary Tract Physiological Phenomena -- Periodicals; 616.62
• DOI: 10.1111/luts.12459
• Languages: English
• ISSNs: 1757-5664

Abstract

Abstract: Objectives: To clarify Japanese real‐world clinical data on the use of desmopressin 25 and 50 μg orally disintegrating tablets (ODT) for male patients with nocturia and evaluate the predictive factors to improve nighttime frequency. Methods: We retrospectively accumulated real‐world clinical data from 27 institutions in Japan. Male patients with two or more episodes of nocturia who received desmopressin ODT for nocturnal polyuria (NP) from 2019 through 2021 were included. The primary endpoint was the change of nighttime frequency until 3 months after desmopressin administration. The secondary endpoints were to clarify the persistence rate, adverse events, and predictive factors of decreasing nighttime frequency. Results: A total of 118 patients were eligible to participate in this study. The persistence rate of desmopressin on the Kaplan‐Meier curve at week 12 was 51.3. The reason for discontinuation was mainly the occurrence of adverse events in 67 patients (56.8%), particularly hyponatremia in 7 patients (5.9%). Nighttime frequencies at baseline, ‐ 1 month and 1 ‐ 3 months after desmopressin administration were 4.1 ± 1.3, 2.9 ± 1.4 ( P < .01), and 2.6 ± 1.3 ( P < .01), respectively. The mean nighttime urine volume voided at baseline was significantly larger in patients whose nighttime frequency decreased by two or more times than in those with a decrease of less than two times. Conclusions: Desmopressin 25 and 50 μg ODT treatments are feasible for male patients with NP in Japanese real‐world clinical practice. Patients with higher voided volumes, particularly in the nighttime, may have great benefit from desmopressin.